Journal Article Preprint Epublish 1 citation
PubMed: 40343022 DOI: 10.1101/2025.04.27.25326360
Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.
medRxiv
Authors: Menayit Tamrat Dresse, Pamela C L Ferreira, Akshay Prasadan, Jihui L Diaz, Xuemei Zeng, Bruna Bellaver, Guilherme Povala, Victor L Villemagne, M Ilyas Kamboh, Ann D Cohen, Tharick A Pascoal, Mary Ganguli, Beth E Snitz, C Elizabeth Shaaban, Thomas K Karikari
Affiliations
- Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Department of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA 15213, USA.
- Department of Statistics & Data Science, Dietrich College of Humanities and Social Sciences, Carnegie Mellon University, Pittsburgh, PA, 15213, USA.
- Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Abstract
INTRODUCTION
Using the ATN framework, we evaluated the potential of plasma biomarkers to identify abnormal brain amyloid-beta (Aβ) positron emission tomography (PET), tau-PET and neurodegeneration in a socioeconomically disadvantaged population-based cohort.
METHODS
Community-dwelling dementia-free (n=113, including 102 (91%) cognitively normal) participants underwent ATN neuroimaging and plasma biomarker assessments.
RESULTS
Plasma Aβ42/Aβ40, p-tau181, and p-tau217 showed significant associations with Aβ-PET status (adjusted odds ratio [AOR] of 1.74*10 -24, 1.47, and 3.43*10 3 respectively [p-values<0.05]), with p-tau217 demonstrating the highest classification accuracy for Aβ-PET status (AUC=0.94). Plasma p-tau181 and p-tau217 showed significant associations with tau-PET status (AOR: 1.50 and 22.24, respectively, p-values<0.05), with comparable classification accuracies for tau-PET status (AUC=0.74 and 0.70, respectively). Only plasma NfL showed significant association with neurodegeneration based on cortical thickness (AOR=1.09, p-value<0.05).
CONCLUSION
Our findings highlight potential of plasma p-tau217 as a biomarker for brain Aβ and tau pathophysiology, p-tau181 for tau abnormalities, and NfL for neurodegeneration in the community.
MeSH
Dementia, Neuroimaging, Brain, Classification, Biomarkers, Plasma